MDXG (MiMedx Group) ROE % Adjusted to Book Value : 3.86% (As of Sep. 2024)

View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group ROE % Adjusted to Book Value?

MiMedx Group's ROE % for the quarter that ended in Sep. 2024 was 18.55%. MiMedx Group's PB Ratio for the quarter that ended in Sep. 2024 was 4.80. MiMedx Group's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was 3.86%.

MiMedx Group ROE % Adjusted to Book Value Historical Data

The historical data trend for MiMedx Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group ROE % Adjusted to Book Value Chart

MiMedx Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-2.49

12.03

MiMedx Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															Negative Equity	38.73	3.40	7.20	3.86

Competitive Comparison of MiMedx Group's ROE % Adjusted to Book Value

For the Biotechnology subindustry, MiMedx Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiMedx Group's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MiMedx Group's ROE % Adjusted to Book Value falls into.

MiMedx Group ROE % Adjusted to Book Value Calculation

MiMedx Group's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	108.14%	/	8.99
	=	12.03%

MiMedx Group's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	18.55%	/	4.80
	=	3.86%

MiMedx Group ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of MiMedx Group's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

MiMedx Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062

Website

https://www.mimedx.com

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Executives

Hulse William Frank Iv	officer: General Counsel	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow	officer: Chief Operating Officer	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rice Doug	officer: Chief Financial Officer	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper	officer: Chief Executive Officer	BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein	officer: EVP, Research and Development	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson	officer: Chief Financial Officer	BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan	officer: Chief Accounting Officer	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Rohit Kashyap	officer: EVP & Chief Commercial Officer	8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright	director, officer: Chief Executive Officer	C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves	officer: SVP & Chief Compliance Officer	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner	officer: SVP, Operations & Procurement	1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner	director	618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani	director	1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins	director	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604